Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
SARS-CoV-2 mutations 'do not increase transmissibility'
Thurs November 26th - None of the SARS-CoV-2 virus mutations that have been documented so far increase transmissibility in humans, a new study has shown. More
Midlife high blood pressure linked to elderly brain damage
Thurs November 26th - High blood pressure in middle age is associated with the development of more extensive brain damage when elderly, researchers report today. More
Activity can offset sedentary lifestyle - WHO says
Thurs November 26th - Exceeding the recommendations for weekly physical activity can offset the health harms associated with prolonged sitting, says new guidelines from the World Health Organisation. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...

Chemotherapy after surgery halves risk of kidney cancer relapse

Friday March 6th, 2020

Chemotherapy halves the risk of a rare form of kidney cancer returning following surgery, according to the findings of a major trial reported today.

The patients, with cancer of the ureter and renal pelvis, who received chemotherapy within three months of surgery had an increased chance of living cancer free for three years or more, researchers said.

The rare cancer is often diagnosed at a late stage and more than half of patients die, but the POUT trial, led by The Institute of Cancer Research, London, and the Lancashire Teaching Hospitals NHS Foundation Trust, found that treating ureter and renal pelvis cancer patients with platinum-based chemotherapy after surgery reduced the risk of dying or returning by 55%.

The trial involved 261 people with cancer of the ureter and renal pelvis and assessed the benefit of giving people four cycles of a combination of two chemotherapies compared with the current standard of treatment, where patients are actively monitored to spot signs of their cancer coming back after having surgery.

The results, published in The Lancet, found that 71% of patients given chemotherapy survived for three years or more after joining the trial and the disease did not return. This compares with 46% of patients who were on surveillance.

Professor Emma Hall, professor of oncology clinical trials at The Institute of Cancer Research, London, co-ordinator of the study, said: “Our clinical trial has found a considerable benefit of giving chemotherapy to people with cancers that start in the tube leading from the kidney to the bladder – cutting the risk of dying or the disease coming back after surgery by more than half.

“Giving chemotherapy after surgery could give people with this rare form of cancer years more to spend quality time with their families. The results of our study are set to change clinical practice in the UK and internationally, and I’m hopeful that patients will start benefiting very soon.”

Dr Rachel Shaw, Research Information Manager at Cancer Research UK, added: “Thanks to this practice-changing trial, we now have more insight into the best way to treat this rare type of kidney cancer. We hope to see this adopted as the standard treatment in the near future, giving patients the best chance of beating the disease.”

The team now plans to study the benefit of adding immunotherapy or targeted treatment to chemotherapy in this form of the disease.

Lancet 6 March 2020

Tags: Cancer | Internal Medicine | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)